Cancer is a major global health challenge, marked by significant mortality rates. Despite advancements in targeted therapies and immunotherapies, the efficacy of these treatments is often hampered by tumor heterogeneity, adaptive responses, and therapeutic resistance. Understanding the underlying mechanisms of tumor progression is essential to identify new treatment vulnerabilities. In this evolving landscape, RNA modifications, particularly those mediated by fat mass and obesity-associated protein (FTO), have gained prominence in cancer biology.
FTO is the first identified m6A demethylase, indicating it plays a crucial role in regulating N6-methyladenosine (m6A) modifications on RNA. This enzyme exerts influence on various RNA species, thereby impacting processes like splicing, stability, and translation. Importantly, FTO is recognized as a context-dependent regulator in cancer, with its functional outputs influenced by factors such as tumor type and upstream signaling pathways. In some cancers, FTO acts as an oncogene, while in others, it plays a tumor-suppressive role, reflecting its functional duality.
This review aims to synthesize current evidence surrounding FTO's complex roles, particularly its impact on the tumor immune contexture. The foundational understanding of FTO in both promoting and inhibiting tumor dynamics is essential to elucidate its contributions to immune evasion and therapeutic resistance.
FTO has been implicated in various mechanisms that shape the tumor immune microenvironment. For instance, it influences metabolic pathways that contribute to immune exclusion, competitive dynamics with immune cells, and alterations in stromal components. These alterations are pivotal in modulating the PD-L1 expression, which plays a critical role in immune checkpoint signaling.
The interplay between FTO and immune checkpoints like PD-L1 can dictate the effectiveness of therapeutic interventions. By modulating the expression of PD-L1, FTO affects how tumors evade immune responses, which poses implications for the success of immune checkpoint blockade therapies. Targeting FTO thus holds promise as a potential strategy to enhance the efficacy of existing immunotherapies.
The contribution of FTO in mediating resistance to numerous therapies, including chemotherapy and targeted approaches, underscores its significance in cancer treatment landscapes. Evidence suggests that FTO's epitranscriptomic functions can lead to differential responses in cancer therapies, with potential links to metabolic reprogramming that sustain tumor cell survival under therapeutic pressure.
Emerging literature supports the concept that various molecular nodes converge around FTO's regulatory functions in relation to immune dynamics and treatment efficacy. Understanding these converging pathways is essential for developing holistically informed therapeutic strategies that can overcome resistance mechanisms.
Recent advancements in pharmacological strategies targeting FTO include the development of FTO inhibitors and FTO-degraders. Preclinical evaluations of these agents provide insights into their potential therapeutic applications alongside traditional immunotherapies. These strategies aim to redefine treatment paradigms by integrating epitranscriptomic frameworks into clinical practice.
Despite progress, the mechanistic understanding of FTO remains heterogeneous and occasionally contradictory across studies. Rigorous calibration of evidence is critical in drawing coherent conclusions regarding its functions and therapeutic implications. An integrated approach can bridge existing knowledge gaps and foster reproducibility in research outcomes.
To harness the full potential of targeting FTO, it is vital to formulate testable hypotheses that can guide future investigations and clinical trials. Translating FTO's regulatory roles and reader-dependent functions into clinically actionable insights will require a robust framework for biomarker stratification and patient selection.
FTO serves as a critical regulatory node that influences cancer progression through its context-dependent interactions in the immune microenvironment and responses to therapies. As research continues to elucidate its multifaceted roles, targeting FTO provides a promising direction in the quest for more effective cancer treatments.